CBI 2026 – XDC Drug Development Conference

Currently, antibody-drug conjugates (ADCs) have entered a critical phase characterized by intensive clinical advancement and commercialization. Meanwhile, emerging technological platforms such as peptide-drug conjugates (PDCs) and radionuclide-conjugated drugs are transitioning from early-stage research to clinical exploration. There is an increasingly clear demand among industry professionals for exchanges of experience across the entire development lifecycle, including target selection, clinical development, and chemistry, manufacturing, and controls (CMC) implementation.

The inaugural lineup of speakers has been confirmed, bringing together industry experts from multinational pharmaceutical companies, leading domestic pharma enterprises, and emerging biotech firms in Suzhou. The two-day conference will focus on three core issues: how to select targets, how to advance clinical development, and how to navigate CMC requirements—offering practical insights and actionable strategies across the entire process, from early-stage R&D and clinical trial design to scaled-up manufacturing and regulatory submission for market approval. Y

You are cordially invited to register and attend free of charge!

Dates: September 4-5, 2026

Location: Hall B, Booth B105, Suzhou International Expo Center, Suzhou, China

Co-organizers: Auscan Biologics, PharmCube